You are here

Article Text

Article menu
Download PDFPDF
Letter
Clinical improvement in cystic fibrosis following anti-tumourous chemotherapy
  1. S Eisen1,
  2. H Painter2,
  3. S C Hyde2,
  4. J Davies3,
  5. A Jaffé4
  1. 1University College London Medical School, London, UK
  2. 2Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, University of Oxford, UK
  3. 3Department of Gene Therapy, Imperial College at National Heart and Lung Institute, London, UK
  4. 4Portex Respiratory Medicine Unit, Great Ormond Street Hospital for Children, London and Institute of Child Health, London, UK
  1. Correspondence to:
    Dr A Jaffé
    Consultant and Honorary Senior Lecturer in Respiratory Research, Portex Respiratory Medicine Unit, Great Ormond Street Hospital for Children NHS Trust and Institute of Child Health, Level 6, Cardiac Wing, Great Ormond Street Hospital for Children NHS Trust, Great Ormond Street, London WC1N 3JH, UK; a.jaffeich.ucl.ac.uk

https://doi.org/10.1136/adc.2004.061275

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Clinical improvement in respiratory function in patients with cystic fibrosis (CF) has been reported following treatment with antitumourous chemotherapy.1,2 It has been suggested that long term upregulation of genes encoding proteins promoting multidrug resistance (MDR), including MDR P glycoprotein, may complement a function of the CFTR protein which is deficient in CF and may be the mechanism by which macrolides exert their effect in CF.1,3 Previous reports …

    View Full Text